Spyre Therapeutics Inc. (SYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.88B
Last updated: Nov 17, 2026 at 11:06 AM ET
Spyre Therapeutics Inc. (SYRE) Stock Forecast
Analysts expect Spyre Therapeutics (SYRE) to earn -$3.04 per share in the fiscal year ending Dec 31, 2026. Of 18 analysts, 17 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.6% |
| Buy | 16 | 88.9% |
| Hold | 1 | 5.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$3.04
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.69
- EPS consensus
- Next report
- Feb 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$3.04 | -$3.95 to -$2.52 | 13 |
| Dec 31, 2027 | -$3.69 | -$4.55 to -$2.36 | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.93 for the quarter ending Dec 31, 2026 to -$0.92 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.93 | -$1.93 to -$0.62 | 17 |
| Mar 31, 2027 | -$0.92 | -$1.10 to -$0.67 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.04 | -$2.85 | -$2.87 | -$2.88 | -$2.85 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.69 | -$3.55 | -$3.52 | -$3.52 | -$3.42 | N/A |
| Quarter ending Mar 31, 2027 | -$0.92 | -$0.82 | -$0.84 | -$0.84 | -$0.79 | N/A |
Frequently Asked Questions About SYRE
What is the SYRE stock forecast?
Consensus analyst estimates put Spyre Therapeutics's EPS at -$3.04 for the fiscal year ending Dec 31, 2026. The consensus rating from 18 analysts is Buy.
How do analysts rate SYRE stock?
Of 18 analysts covering Spyre Therapeutics, 1 rates it Strong Buy, 16 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SYRE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.04, with estimates from -$3.95 to -$2.52 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.69, with estimates from -$4.55 to -$2.36 from 13 analysts.
How many analysts cover SYRE?
18 analysts rate Spyre Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SYRE pages: Overview, Earnings, Forecast, Financials, Competitors